Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 1, 2005
Business Overview: IRIDEX is a worldwide provider of semiconductor-based laser systems for ophthalmology (treating eye diseases like AMD, diabetic retinopathy, and glaucoma) and dermatology (treating skin conditions and hair removal). Products are sold domestically via a direct sales force and internationally through 68 independent distributors in 107 countries.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2004 | Fiscal 2003 | Fiscal 2002 |
|---|---|---|---|
| Total Sales | $32,810 | $31,699 | $30,634 |
| Gross Profit | $14,888 | $14,071 | $13,588 |
| Gross Margin | 45.4% | 44.4% | 44.4% |
| Operating Loss | ($1,076) | ($48) | ($181) |
| Net Income (Loss) | ($402) | $371 | $150 |
| Cash & Equivalents | $10,381 | $10,541 | $9,186 |
| Working Capital | $25,342 | $28,462 | $28,072 |
| Total Debt | $0 | $0 | $0 |
Note: The company has a $4.0 million unsecured line of credit with no borrowings outstanding as of January 1, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 3.5% to $32.8 million, driven by an 11.1% increase in international sales ($12.9 million) which offset a 0.9% decline in domestic sales.
- Segment Performance: Ophthalmology sales grew 6.1% to $27.8 million (84.6% of total revenue). Dermatology sales declined 8.7% to $5.1 million, primarily due to a 20.6% drop in domestic dermatology unit sales.
- Profitability Impact: The company reported a net loss of $402,000 in 2004 compared to a net income of $371,000 in 2003. This reversal was primarily caused by a one-time $1.0 million charge to establish a reserve for unpaid sales taxes and interest, plus a $0.3 million increase in the allowance for doubtful accounts.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 13.6% to $11.5 million, largely due to the aforementioned sales tax reserve and consulting fees.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A expenses to decrease in absolute dollars in 2005 as the one-time sales tax charge will not recur, though Sarbanes-Oxley compliance costs will increase. R&D expenses are expected to increase slightly due to new product development.
- New Products: The company launched the IQ810 infrared platform for ophthalmology and the VariLite dual-wavelength laser for dermatology in 2004. Future growth is expected from these products and the adoption of Minimum Intensity Photocoagulation (MIP) procedures.
- Clinical Trials: Results from the TTT4CNV clinical trial for wet AMD showed no statistically significant benefit in the overall intent-to-treat evaluation, though subgroup analysis showed benefits for patients with severe vision loss. Further validation is required.
- Key Risks:
- Reimbursement: Sales are heavily dependent on third-party payer coverage. CMS reimbursement policies for AMD procedures have historically fluctuated, impacting sales of specific laser systems.
- Competition: Intense competition from pharmaceutical alternatives (e.g., Visudyne, Macugen) and other laser manufacturers.
- Supply Chain: Reliance on sole-source suppliers for critical components like laser diodes and optics.
- Accounting Changes: Implementation of SFAS No. 123R (Share-Based Payment) in 2005 will require expensing stock options, which will reduce reported earnings.
Investor Verification Checklist
- Sales Tax Reserve: Verify the status of voluntary settlement agreements with states regarding the $1.0 million sales tax reserve and whether additional liabilities may arise.
- Reimbursement Policies: Monitor CMS and private payer coverage decisions for Transpupillary Thermotherapy (TTT) and other MIP procedures, as these directly drive ophthalmology sales.
- Stock-Based Compensation: Assess the impact of SFAS No. 123R adoption on future earnings per share, as pro forma net loss would have been significantly higher under fair-value accounting.
- International Exposure: Review currency fluctuations and geopolitical risks, as international sales comprise nearly 40% of revenue and are denominated in USD.
- Inventory Levels: Monitor inventory reserves and obsolescence risks, particularly for aging dermatology products and components for new product introductions.